We read with interest the article by Sibbing et al on the activating CYP2C19*17 variant that unveils a more complicated picture of the CYP2C19 locus. The work by Sibbing et al complements investigations showing the opposite effect of the inactivating CYP2C19*2 variant, which accounts for 12% of clopidogrel response variability. 2 The *2 and *17 variants, 19 959 base pairs apart and in linkage disequilibrium, are not independent of one another. Therefore, individuals heterozygous or homozygous for the *17 allele are less likely to carry the *2 allele, whereas those with 0 copies of the *17 allele ("wild type" at the *17 locus) are more likely to carry the *2 allele. It follows that greater clopidogrel response in *17 allele carriers can be partly or completely attributed to decreased *2 allele frequency. In our opinion, to dissect whether the *17 allele is a true effector of clopidogrel response independently of the *2 allele, the authors should have also genotyped for the *2 variant and performed a statistical adjustment for its effect in a regression-based analysis, and/or they should have performed an analysis of *17-*2 diplotypes. A similar analysis suggested that the *2 variant could account for most or all of the association with clopidogrel response at the CYP2C19 locus. 2 In addition, to better understand the mechanistic link implied by *17 carrier status, it would be of interest to determine whether platelet function tests were also associated with bleeding risk and whether the CYP2C19 genotype was a mediator of these effects (again through regression-based analysis). In our previous study, 2 platelet function could fully account for the association between CYP2C19*2 genotype and cardiovascular events. Finally, the higher prevalence of active smokers in *17 homozygotes may have influenced platelet reactivity. 3 Studies to open the previously proposed therapeutic window for thienopyridine therapy through genotype-guided antiplatelet regimens that may include tailoring clopidogrel dosing, selected use of newer reversible and irreversible P2Y12 inhibitors, and concomitant thrombin receptor blockade are on the horizon. 4 The work by Sibbing et al is an important contribution in this area.
